Related Experiment Video
Updated: Jun 15, 2026
Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model
Published on: April 24, 2020
Activated synovial macrophages as targets for osteoarthritis drug therapy
1Department of Rheumatology, Cardiff University, Heath Park, Cardiff CF144XN, UK. BondesonJ@cf.ac.uk
Abstract:
The great success of targeted biologic therapy against rheumatoid arthritis (RA) in recent years has meant that much research has been devoted to investigating the pathophysiology of osteoarthritis (OA) in the hope of defining novel therapeutic targets. In contrast to RA, with its pannus and erosions, OA has long been thought of as a degenerative disease of cartilage, with secondary bony damage and osteophytes. But in recent years, the importance of the synovium, and in particular the synovial macrophages, in OA, has been highlighted in both in vitro and in vivo studies. This review will discuss the potential of synovial macrophages and their mediators, in particular the proinflammatory cytokines tumour necrosis factor alpha and interleukin-1, as potential therapeutic targets in OA.
Insights
Synovial macrophages are key players in osteoarthritis (OA) pathogenesis. Targeting these cells and their inflammatory mediators, like tumor necrosis factor alpha and interleukin-1, offers promising new therapeutic strategies for OA.
Area of Science:
- Rheumatology and immunology, focusing on osteoarthritis (OA) and inflammatory processes.
Background:
- Rheumatoid arthritis (RA) treatments have advanced, prompting investigation into osteoarthritis (OA) pathophysiology for new therapeutic targets.
- OA was traditionally viewed as cartilage degeneration, but recent research highlights the role of the synovium, especially synovial macrophages.
Purpose of the Study:
- To review the potential of synovial macrophages as therapeutic targets in osteoarthritis.
- To discuss the role of synovial macrophage mediators, such as tumor necrosis factor alpha and interleukin-1, in OA pathogenesis and treatment.
Main Methods:
- Review of in vitro and in vivo studies examining the role of synovial macrophages in osteoarthritis.
- Analysis of scientific literature on inflammatory cytokines and their involvement in OA.
Main Results:
- Synovial macrophages and their mediators are increasingly recognized as critical factors in OA development.
- Proinflammatory cytokines like tumor necrosis factor alpha and interleukin-1 are implicated in OA pathophysiology.
Conclusions:
- Synovial macrophages represent a significant potential therapeutic target for osteoarthritis.
- Targeting synovial macrophages and their key mediators could lead to novel treatment strategies for OA.
